Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.
With the emergence of disease-modifying strategies for the treatment of Alzheimer's disease, impetus to diagnose the condition in its early 'preclinical' stages -before significant brain damage has occurred -has intensified. Fortunately, advances in technology and in our perspective on what defines Alzheimer's disease may soon make such antecedent diagnosis possible.
Since their first description, in 1907 (ref. 1) , 'senile' plaques and neurofibrillary tangles (NFTs) have been the hallmark histopathological features of Alzheimer's disease and are employed by three sets of diagnostic histological criteria [2] [3] [4] . Historically, they have also been associated with the dementia caused by the disease. It is clear, however, that these lesions begin to accrue in significant amounts in many 'cognitively normal' elderly individuals 5 and, probably together with other damage, need to reach a threshold before the clinical manifestations we know as dementia are observed. A growing body of evidence now supports the idea that amyloid plaques and NFTs actually define (but do not fully represent) the disease process, which also involves inflammation as well as neuronal, axonal and synaptic loss and dysfunction. All of these changes appear to begin before significant cognitive decline occurs. Consistent with this, neuropathological studies involving large numbers of non-demented subjects have identified significant Alzheimer's disease pathology in the brains of older individuals 6, 7 . Neocortical cerebral amyloid deposits have been identified in approximately 50% of brains from individuals more than 75 years old 7 .
In contrast, the prevalence of Alzheimer's disease dementia does not reach 50% until age 85 or more 8 . The onset of very mild dementia is correlated best not with plaque or NFT burden but with significant synaptic and neuronal loss 9, 10 . Together, these data support the concept of preclinical Alzheimer's disease, a phase during which plaques and, subsequently, NFTs accumulate for ~10-15 years before the synaptic and neuronal loss they accompany manifest as cognitive decline 9 ( Fig. 1 ). This concept fits with genetic, biochemical and animal model data which demonstrate that the aggregation of the amyloid-β peptide plays a necessary part 11 , especially in the preclinical phase of the disease, and that aggregation of microtubule-associated protein tau, which occurs in bulk later, drives neurodegeneration during and just before the clinical phase.
Nevertheless, the pathological process of Alzheimer's disease currently is noticeable during life only when it manifests clinically. The early clinical signs that are believed to result from Alzheimer's disease (decline in memory and executive functions) are referred to in different ways by clinicians.
Some report this syndrome as very mild dementia of the Alz heimer type 12 .
Others prefer the term mild cognitive impairment 13 . Because many of the biomarkers that provide insight into the underlying pathology of Alzheimer's disease are not yet used in day-to-day patient care, these diagnoses reflect attempts to describe clinical syndromes in the absence of definitive proof of the underlying pathology. However, in combination with clinical methods and cognitive tests, biomarkers will soon contribute to a more accurate assessment of cognitive impairment and its cause (Box 1). Perhaps more importantly, biomarkers are expected to enable clinicians to identify and monitor the pathology caused by Alzheimer's disease before the onset of cognitive dysfunction, and suggest prognosis.
The purpose of this Review is to discuss the most promising targets, techniques and implications of Alzheimer's disease biomarker research so far. Advances in neuroimaging now allow accurate measurements of atrophy, metabolism, inflammation, plaque and NFT abundance, and 'default network' activity in the brain. Furthermore, fluid biomarker research has employed powerful 'unbiased' screening approaches, increasingly sensitive proteomics techniques and novel applications of mass spectrometry to identify new fluid biomarkers and even monitor fluid biomarker metabolism in living subjects. The use of genetics in combination with biomarkers will probably provide more diagnostic and prognostic information than the use of biomarkers alone. However, a detailed discussion of the genetics of Alzheimer's disease is beyond the scope of this Review. The most up-to-date information on the genetics of the disease can be found at the Alzheimer Research Forum (http://www.alzgene.org).
Imaging atrophy and aggregates of amyloid-β and tau
Although cellular resolution has not yet been achieved, recent advances in functional and molecular neuroimaging have provided insights into brain structure and physiology, allowing the study of specific proteins and protein aggregates in ways that are difficult or impossible to achieve through autopsy. Moreover, neuroimaging biomarker studies can immediately correlate data with structure and (dys)function.
The characteristic patterns of cortical and hippocampal volume loss in advanced Alzheimer's disease are well known but difficult to quantify with precision during post-mortem examination. Atrophy is particularly difficult to measure in the early stages of the disease, when it superficially resembles the inconspicuous volume loss commonly observed among elderly individuals without neurodegeneration ('healthy' ageing). 
Biomarkers
Distinguishing such subtle differences is not difficult using high-resolution quantitative magnetic resonance imaging. Applied longitudinally, this technique can distinguish between the global atrophy rate of healthy ageing and that of the disease 14 and predict progression from normal cognition to mild cognitive impairment 15 and from the latter to Alzheimer's disease on the basis of regional volume losses and ventricular expansion over time 16 ( Fig. 2b, c) . However, atrophy and cognitive decline occur in most neurodegenerative disorders, and although volume changes in certain brain regions may be suggestive of, or consistent with, Alzheimer's disease, they do not reveal the underlying pathology.
Patterns of plaque and NFT formation in Alzheimer's disease have been thoroughly studied. Until recently, however, ante-mortem examination of these pathological changes has been nearly impossible. Within the past decade, a number of radiological-contrast compounds have been developed that specifically bind to and highlight pathological structures in the central nervous system, including amyloid plaques, neurofibrillary tangles, activated microglia and reactive astrocytes. , but no agent that selectively binds to aggregates of tau has yet been described. Such a discovery would be a major advance for molecular imaging.
Of the amyloid-binding compounds,
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C-PIB (PIB, Pittsburgh compound B), has been the most extensively studied and applied in research into Alzheimer's disease. Uptake of PIB can be measured by positronemission tomography (PET). In individuals with the disease, increased retention of PIB shows a very specific pattern that is restricted to brain regions typically associated with amyloid deposition 18 ( Fig. 2b, c) . Notably, an appreciable number of cognitively normal individuals over the age of 60 show a PIB signal pattern indistinguishable from that of individuals with Alzheimer's disease, suggesting that measurement of PIB using PET can detect a preclinical stage of the disease 19 . When PIB PET was performed and concentrations of Aβ 42 peptide (the 42-residue-long isoform of amyloid-β) in the cerebrospinal fluid were measured at the same time in individuals ranging from the cognitively normal to those with Alzheimer's disease, two discrete groups were distinguished: 'PIB-negative' individuals and 'PIB-positive' ones. Without exception, the PIB-positive group had low Aβ 42 levels in the cerebrospinal fluid 20 ( Fig. 2a) . This finding is consistent with the idea that soluble Aβ 42 is retained in the brain once plaques are formed. Larger longitudinal studies of cognitively normal subjects, comparing those with amyloid to those without amyloid, will be required to evaluate whether the presence of amyloid confers a greater risk of 'conversion' to dementia. An initial study suggests that this is the case 21 .
Complementing these radiological studies of amyloid deposition, other PET labelling agents have been developed to image inflam mation as reflected by activated microglia and reactive astrocytes that surround plaques. Among the changes that microglia undergo on activation, increased expression of the peripheral benzodiazepine receptor has been exploited as a target for the radiological compounds [ Only the third of these has been reported in studies of Alzheimer's disease in humans, in conjunction with PIB. In these studies of individuals with mild cognitive impairment or Alzheimer's disease, PK11195 and PIB signals showed similar anatomical patterns, but their intensities did not show regional correlation 24 ; among subjects with Alzheimer's disease, there was an inverse correlation between PK11195 signal and cognitive performance. These findings suggest that microgliosis occurs concomitantly with amyloid deposition and may have a direct role in cognitive dysfunction. However, better imaging agents are needed to visualize microglial activation in Alzheimer's disease. Like microglia, astrocytes show changes on association with plaques, including elevation of monoamine oxidase B activity 25 , but studies that use inhibitors of monoamine oxidase B as radiotracers in Alzheimer's disease are only now appearing 26 . Larger studies will be needed to understand whether imaging inflammation may inform subject selection for clinical trials, contribute to predictions of prognosis and allow monitoring of response to therapy.
Watching the mind at work
Neurons of the medial temporal lobe and hippocampus are particularly susceptible to loss in Alzheimer's disease, and their loss seems to co incide with the onset of clinically significant cognitive impairment. Functional magnetic resonance imaging is believed to provide a measure of synaptic activity, and this technique seems to show hypoactivation of the medial temporal lobe memory system in the clinical stages of the disease. However, hyperactivation of the same structures seems to occur in mild cognitive impairment, when memory is only mildly impaired and neuronal loss is less severe; this increased activity may represent an attempt to compensate for functional inefficiencies 27 . Although the medial temporal lobe memory system seems to be selectively vulnerable in Alzheimer's disease, other regions of the cortex (for example the posterior cingulate cortex, the precuneus, the temporoparietal region and the medial frontal cortex) also experience amyloid deposition, gliosis and atrophy during the long preclinical phase 28 ( Fig. 2) . Accordingly, abnormalities of these cortical regions in individuals with mild cognitive impairment and mild Alzheimer's disease can be seen by using functional magnetic resonance imaging 27 and single-photonemission computed tomography (which measures regional blood flow), and can be used to predict progression from mild cognitive impairment to Alz heimer's disease 29 .
As might be expected for brain regions that display atrophy, neuronal loss and reduced perfusion, these cortical regions also show evidence of decreased glucose metabolism in subjects with the disease, as measured by fluorodeoxyglucose PET 28 ( Fig. 2b, c) . Additionally, although its accuracy has not been thoroughly compared with that of other biomarkers assessed in the same subjects, fluorodeoxyglucose PET has been reported to predict conversion from cognitive normalcy to mild cognitive impairment 30 and thence to Alzheimer's disease 31 . Furthermore, fluorodeoxyglucose PET has been used to demonstrate the effects of pharmacological agents, correlated with level of cognitive impairment 32 . Therefore, these imaging measures of synaptic activity (functional magnetic resonance imaging), perfusion (single-photon-emission computed tomography) and glucose metabolism (fluorodeoxyglucose PET) may serve as biomarkers to guide diagnosis and to predict and monitor progression, and might be used in the future to evaluate responses to therapy.
The default network
Although imaging studies have contributed tremendously to our understanding of Alzheimer's disease by allowing us to compare afflicted subjects with age-matched controls, valuable insights into the pathophysiology of the disease have also been gained through the study of young, healthy volunteers. In 2001, the hypothesis of a 'default' mode of human brain activity 33 that is engaged during internally focused tasks such as remembering past events, imagining the future and considering the perspectives of others (comprehensively reviewed in ref. 34 ) was put forward on the basis of numerous functional imaging studies done over the past four decades. In 2005, a remarkable correlation was demonstrated between the neuroanatomical substrates of the default network (the medial temporal lobe and hippocampus, the medial prefrontal association cortex, the posterior cingulate cortex, the retro splenial cortex, the inferior parietal cortex and the lateral temporal lobe) and the anatomical distributions of amyloid deposition, atrophy, glucose metabolism and blood flow in Alzheimer's disease 28 (Fig. 2c) . It was suggested that young-adult activity and metabolism patterns might be conducive to amyloid deposition in Alzheimer's disease. Indeed, amyloid-β production is dependent on synaptic activity 35, 36 , and those regions of the default network that show high resting metabolism are also those that are most affected in subjects with the disease. It seems clear that any substantive insight into the aetiological connection between default-network metabolism and the pathology of Alzheimer's disease will contribute seminally to our understanding of the illness.
Amyloid-β and tau as Alzheimer's disease biomarkers
Without going so far as to perform brain biopsy or place a microdialysis catheter directly into the brain 37 , the sampling of cerebrospinal fluid and plasma represents the most direct and convenient means to study the biochemical changes occurring in the central nervous system. Therefore, these fluids are the most attractive resources for ongoing research into Alzheimer's disease biomarkers. Implicated by biochemical and immunohistological studies of Alzheimer's brain tissue, the major protein constituents of the pathology of the disease (Aβ 40 , Aβ 42 , tau and phosphorylated forms of tau) have emerged as the current leading diagnostic and prognostic fluid biomarkers.
Amyloid-β is a secreted peptide of unknown physiological function that is cleaved from amyloid precursor protein by the sequential activities of β-secretase and γ-secretase enzymes. The majority of amyloid-β is produced in the brain, but it effluxes into the cerebrospinal fluid and plasma, appearing in relatively high and low concentrations, respectively. Amyloid-β occurs in multiple forms ranging from 38 to 43 amino acids in length. Among these, Aβ 40 is the most abundant species, but Aβ 42 seems to be essential for initiating amyloid-β aggregation, and is considered central to the amyloid cascade hypothesis of Alzheimer's disease 11 . Of these two species, Aβ 42 has emerged as a more useful biomarker for Alzheimer's disease than its shorter counterpart, Aβ 40 , most probably in reflection of their roles in the pathogenesis of the disease.
Although the finding is initially counter-intuitive, the mean concentration of Aβ 42 in the cerebrospinal fluid is significantly reduced in subjects with Alzheimer's disease relative to age-matched controls 38 ( Fig. 3b) ; this phenomenon is thought to result from deposition of the peptide in plaques, preventing its transit from the brain into the cerebrospinal fluid (the 'amyloid sink' hypothesis). In support of this hypothesis, when ante-mortem cerebrospinal-fluid Aβ 42 concentrations are compared with PET PIB scan results or with post-mortem measurements of brain amyloid-β load, virtually all individuals with fibrillar amyloid-β deposits show low concentrations of Aβ 42 in the cerebrospinal fluid, indep endent of cognitive status 20, 39, 40 (Fig. 2a) . Thus, cerebrospinal-fluid Aβ 42 may serve as both a diagnostic biomarker for Alzheimer's disease and a surrogate biomarker for amyloid deposition.
The utility of cerebrospinal-fluid Aβ 42 may not end with diagnosis and surrogacy, however. In several longitudinal studies, especially when combined with information about the levels of tau or phosphorylated tau in the cerebrospinal fluid, cerebrospinal-fluid Aβ 42 has shown a cap acity to predict progression from cognitive normalcy to mild cognitive impair ment or dementia of the Alzheimer's type, and from mild cognitive impair ment to dementia of the Alzheimer's type [41] [42] [43] (Fig. 3c) . Low concentrations of cerebrospinal-fluid Aβ 42 may also be a harbinger of amyloid deposition; recently, we identified a class of individuals who have low concentrations of cerebrospinal-fluid Aβ 42 but show no evidence of amyloid on PET PIB scans 39 ( Fig. 2a) . The autopsy of one of these individuals showed widespread diffuse -but minimal fibrillar -amyloid-plaque deposits 44 . Thus, Dementia is an acquired syndrome in which there is a decline in memory and thinking that is sufficient to interfere with everyday performance. Some individuals demonstrate deficits either in memory alone or in memory and other cognitive domains that are indicative of an abnormality but are not yet severe enough to be termed dementia. Most people who go on to develop dementia go through a transitional stage that some term very mild dementia and others term mild cognitive impairment or 'cognitively impaired no dementia'. Many different things can lead to cognitive impairment and dementia, including a variety of neurodegenerative disorders, vascular damage, infections, tumours and other causes. Alzheimer's disease is the most common cause of cognitive impairment and dementia in people over the age of 65. Determination that acquired cognitive impairment or dementia is present, and diagnosis of its probable cause, is based on clinical history (especially from a reliable informant), neurological and psychiatric examinations, and certain laboratory tests. The assembled information allows assessment of whether an individual's faculties have decreased relative to their past abilities (intra-individual change) and can be used for determining the level of dementia (very mild, mild, moderate or severe) as well as the most likely diagnosis.
Formal cognitive testing can aid these determinations and is particularly useful in clinical situations in which cognitive symptoms and signs are subtle or are confounded by other medical factors such as depression. A variety of neuropsychological tests can be used to accurately assess the different cognitive domains, including orientation, intellect, language, memory, attention, concentration, executive function, visual/perceptual abilities, sensorimotor function, mood and personality 79 . Serial neuropsychological evaluations are also very useful for tracking the progress of an individual over time relative to an established baseline. At present, the diagnosis of dementia due to Alzheimer's disease can only be confirmed with certainty at autopsy. However, many of the biomarkers reviewed here, when used together with clinical evaluation and cognitive testing, can assist with differential diagnosis and prognosis. To determine the presence of diseases such as Alzheimer's disease before the emergence of cognitive impairment or dementia as detected through neuropsychological testing or by clinicians, antecedent biomarkers will be required. cerebrospinal-fluid Aβ 42 may have utility as a biomarker for diagnosis, plaque burden and prognosis, and may provide the earliest clue to the identification of preclinical Alzheimer's disease (as defined by the emergence of amyloid-β deposition).
The utility of plasma Aβ 42 as a biomarker for Alzheimer's disease is less compelling. Concentrations of Aβ 42 in cerebrospinal fluid and plasma show no apparent correlation 39, 45, 46 . Some studies suggest that the Aβ 40 /Aβ 42 ratio in plasma may be predictive of conversion from cognitive normalcy to mild cognitive impairment and Alzheimer's disease 47, 48 , but the plasma amyloid-β markers do not seem to approach the predictive value of cerebrospinal-fluid Aβ 42 .
Tau is a cytosolic protein predominantly expressed in neurons, wherein its primary function seems to be regulation of microtubule stability within the axon. This function is regulated by several different post-translational modifications, principally phosphorylation of numerous serine and threonine residues. In Alzheimer's disease, hyperphosphorylated tau often fills the dystrophic neurites of neuritic plaques and is the principal component of the paired helical filaments that constitute NFTs (Fig. 3a) . The precise forms of tau that appear in the cerebrospinal fluid, and the mechanism or mechanisms by which they get there, are not entirely understood, but recent studies 49 demonstrate that virtually all domains of the protein are represented, and it is widely assumed (but not proven) that the major sources of tau and phosphorylated tau in the cerebrospinal fluid of sufferers of Alzheimer's disease are neuronal injury or death and possibly neurofibrillary tangles.
Like Aβ 42 , tau and phosphorylated tau have emerged as important cerebro spinal-fluid biomarkers for Alzheimer's disease. Mean concentrations of tau and phosphorylated tau are higher in the cerebrospinal fluid of subjects with Alzheimer's disease than in that of age-matched controls 50 ( Fig. 3b) . These increases appear in the setting of formed fibrillar amyloid deposits 40 (consistent with the amyloid cascade hypothesis), and correlate with both neuritic-plaque density and Braak NFT stage 40 . In conjunction with Aβ 42 , tau and phosphorylated tau seem to be useful as prognostic biomarkers for conversion to dementia from cognitive normalcy or mild cognitive impairment [41] [42] [43] (Fig. 3c) . Together, these results suggest that longitudinal measurements of cerebro spinal-fluid Aβ 42 and tau may allow clinicians to monitor and even predict the progress of Alzheimer's disease pathology throughout its entire course. Of course, the pathophysiology of the disease involves many more processes than amyloid-β deposition and NFT formation. Amyloid precursor protein is cleaved by β-secretase and γ-secretase complexes. Once released as monomers, amyloid-β may form oligomers that are cytotoxic and/or neuromodulatory. To form plaques, amyloid-β must accumulate. Once amyloid-β has formed oligomers and amyloid deposits, microglial cells become activated and migrate towards plaques as they form 51 . Astrocytes become reactive, and numerous inflammatory mediators, signalling molecules, oxidative processes, complement cascades and modulators of protease activities and protein-folding activities are released. Dendrites and axons in the vicinity of plaques become dystrophic as transport processes malfunction. The metabolism of the brain changes 28 . Amyloid-β is deposited in vessel walls. In addition to forming NFTs, neurons show many other changes. Synapses exhibit dysfunction and are lost. Neurons die. Each of these changes -and others not mentioned and not yet recognized -may represent a therapeutic target and may also cause changes in the composition of the cerebrospinal fluid and plasma. Recognizing this potential, many research groups continue to search for other fluid biomarkers that may complement or improve the well-established utility of cerebrospinal-fluid Aβ 42 and tau. 
Oxidative stress and inflammation
Increasing evidence implicates oxidative damage as a mediator of toxicity in Alzheimer's disease. By-products of lipid peroxidation (isoprostanes) and RNA oxidation (8-hydroxyguanine) have shown the most promise as biomarkers. Produced by free-radical-mediated peroxidation of polyunsaturated fatty acids, isoprostanes in cerebrospinal fluid are increased in Alzheimer's disease 52, 53 and may predict the development of mild cognitive impairment and Alzheimer's disease 54 . The utility of plasma isoprostanes as biomarkers for the disease is less promising; some 55 , but not all 56 , studies have found elevated concentrations in subjects with Alzheimer's disease relative to controls. The other oxidative marker, 8-hydroxy guanine, representing oxidized RNA, has been reported to be elevated in the cerebrospinal fluid of subjects with Alzheimer's disease in one small study 57 and is worthy of further research. Inflammation, represented by plaque-associated microglia and astrocytes, is also implicated in Alzheimer's disease pathology. In addition to any immediate role these inflammatory cells may have, their secreted products -including acute-phase proteins such as α 1 -antichymotrypsin (ACT, also known as SERPINA3 protein) 58 and α 2 -macroglobulin (α2M) 59 , activated factors of the classical pathway of complement 60 , and cytokines such as interleukin-1β (IL-1β) and tumour-necrosis factor-α (TNF-α, also known as TNF) -persist within plaques. Although the contribution of these deposited inflammatory mediators to the pathophysiology of Alzheimer's disease is not entirely clear, there is evidence to suggest that they have an important role.
Appearing in cerebrospinal fluid in proportion to cognitive impairment, ACT has emerged as a potential biomarker for Alzheimer's disease 61 , although its utility in plasma -and that of α2M -remains unclear [61] [62] [63] [64] . By comparison, fluid biomarker studies of complement factors (C3a anaphylatoxin chemotactic receptor and C1q) have been inconclusive 65, 66 , as have more traditional fluid biomarker studies of cytokines 67 . In contrast, supporting a role for cytokines in Alzheimer's disease, several groups have measured their spontaneous production by mononuclear cells obtained from the peripheral blood (PBMCs). This approach is relevant to Alzheimer's disease because perivascular macrophages and microglia derived from circulating monocytes may participate in intraparenchymal inflammation in the brain 68 . In one report, PBMCs from sufferers of the disease produced larger amounts of cytokines than PBMCs from controls 69 ; in another study of over 600 participants, increased PBMC production of either IL-1β or TNF-α was associated with increased hazard ratios for developing the disease 67 .
Other recent work, measuring 120 signalling proteins in plasma, suggested that sporadic Alzheimer's disease may be accompanied -and diagnosed in its very early stages -by a systemic inflammatory state characterized by a panel of 18 signalling molecules 70 . If confirmed, this biomarker discovery 70 demonstrates the potential power of multiple biomarkers incorporated into a panel to diagnose Alzheimer's disease accurately, and also illustrates the value of a less-targeted, 'unbiased' , highthroughput approach to biomarker discovery. 
Proteomics
Ongoing advances in mass spectrometry and protein-handling technology continue to broaden the methodological diversity and increase the sensitivity of proteomic analyses; as many as several thousand proteins can now be measured in a sample of human cerebrospinal fluid. Complementing the 'directed' fluid biomarker investigations discussed above, several groups have pursued 'unbiased' proteomics to discover novel Alzheimer's disease biomarkers empirically in cerebrospinal fluid 63, [71] [72] [73] . Using different techniques, these studies have generated multiple lists of candidate biomarker proteins that show individual and collective abilities to 'recognize' and classify samples appropriately. A comprehensive discussion of these proteomic studies is beyond the scope of this Review; however, the following observations are worthy of note.
First, many of the proteins that distinguish the Alzheimer's disease cerebrospinal-fluid proteome reflect the pathological changes already known to occur in the Alzheimer's brain. Therefore, new candidate biomarkers without known relevance to the disease may provide clues into patho physiological processes that are underappreciated or are not yet recognized. Second, in our experience, post-translational modification -limited proteolysis in vivo in particular-seems to be common among cerebro spinal-fluid proteins showing differential abundance in Alzheimer's disease. Yet when proteins are identified by mass spectrometric evaluation of trypsinized fragments, such modifications may be overlooked. This issue has received relatively little attention, despite its critical importance to the design of assays that might be used in validation experiments for these biomarkers. Third, and finally, most proteomics studies reported so far have compared subjects who have Alzheimer's disease with age-matched non-demented controls (or with controls who have a dementia other than Alzheimer's disease) and are therefore designed to identify diagnostic biomarkers. To advance the discovery of predictive or surrogate biomarkers using unbiased proteomics, more studies should compare groups of subjects with Alzheimer's disease that differ in terms of rate of progression, presence of amyloid and tau deposits, or other relevant characteristics.
Monitoring biomarker metabolism and treatment effects
As treatments that target the production or clearance of specific molecules involved in the pathophysiology of Alzheimer's disease come to clinical trial, the capacity to monitor the metabolism of relevant fluid biomarkers before, during and after drug administration would be very helpful in verifying treatment effect and optimizing dosage. To this end, a new in vivo technique has been developed to measure the production and clearance rates of cerebrospinal-fluid proteins in human subjects. In this technique, a stable (non-radioactive) isotope-labelled amino acid (for example 13 C 6 -leucine) is administered intravenously and becomes incorporated into newly synthesized proteins. Cerebrospinal fluid and plasma are sampled using intrathecal and intravenous catheters. Using liquid chromatography and tandem mass spectroscopy (LC-MS/MS) to compare labelled and unlabelled proteins over time and/or at different doses of a candidate therapeutic agent, very precise synthesis, clearance and dose-response curves can be developed. This technique was first applied to determine the synthesis and clearance rates of amyloid-β in the central nervous system 74 and was used more recently in a randomized, double-blind, placebo-controlled study to demonstrate the pharmacokinetic/pharmacodynamic relationship between an inhibitor of amyloid-β synthesis and the absolute rate of amyloid-β synthesis in the central nervous system 75 . The potential of this technique is that it automatically labels all newly synthesized proteins when using the appropriate precursor; as such, it should allow evaluation of the metabolism of other proteins relevant to Alzheimer's disease (and other neuro degenerative diseases) and the metabolism of multiple biomarkers simultaneously.
Future directions
Advances in technology, knowledge and perspective now promise the tools to diagnose, monitor and predict the course of sporadic Alzheimer's disease, even before clinical symptoms begin. Of equal importance is that parallel advances promise treatments for Alzheimer's disease that will make such information far more valuable. Nevertheless, achieving these goals will require a great deal more work. More-effective radiographic biomarkers are needed to monitor central nervous system inflammation and tau pathology, as well as other neurodegenerative features. Likewise, fluid biomarkers are needed that can distinguish Alzheimer's disease from other types of dementia and provide even better prognostic information. Once identified, biomarker assays must be standardized in forms that are amenable for use in existing clinical laboratories and that can be evaluated in suitably large sample sets. To facilitate such biomarker validation studies and provide sufficient statistical power, longitudinally followed cohorts of study participants (including individuals with a dementia other than Alzheimer's disease), complete with uniformly collected and stored specimens, must continue to grow in size and number; a successful example of this is the Alzheimer's Disease Neuroimaging Initiative (http://www.adni-info. org). Finally, once this work has identified a satisfactory panel of ante cedent Alzheimer's disease biomarkers, and one or more effective treatments for the disease have been approved, appropriate clinical guidelines must be developed to support and encourage widespread clinical testing.
In the more distant future, we may be able to evaluate risk for Alzheimer's disease even earlier in life. Just as biomarker data from well-characterized, longitudinally followed cohorts of study participants may be interpreted to guide diagnosis, estimate prognosis and monitor response to treatments, they will also be used to identify genetic markers that are associated with particular biomarker values. In comparison with genetic studies of Alzheimer's disease that rely on less precise diagnoses that are clinically based, genetic studies based on quantitative endophenotype data can provide greater statistical power 76 . Indeed, quantitative biomarker data have already been used with success in genetic studies of Alzheimer's disease. Elevated concentrations of cerebrospinal-fluid tau and phosphorylated tau have been found to associate with single-nucleotide polymorphisms in the MAPT gene (from which tau protein is produced). Likewise, concentrations of amyloid-β in cerebrospinal fluid have been found to associate with polymorphisms in several genes 76 . In this way, by 'converting' endophenotype data derived from fluid and imaging biomarkers to novel genetic biomarkers, it may be possible to identify individuals at greater risk of developing Alzheimer's disease and, in the near future, provide treatment options before even a single plaque has formed. 
